Patient Preferences and Therapeutic Satisfaction with Topical Agents for Rosacea: A Survey-Based Study
Temporal Trends in Survival and Healthcare Costs in Patients with Multiple Myeloma in the United States
Approximately 30,000 new cases of multiple myeloma are diagnosed annually in the United States, and 12,650 deaths annually are attributed to multiple myeloma.
Improved Clinical Outcomes with Newer Multiple Myeloma Therapies Associated with Increased Resource Utilization and Financial Burden
Prospective Bundled Payments in a Changing Environment: The Experience of a Self-Funded, State-Sponsored Plan
For decades, healthcare reimbursement has been based on the quantity of services delivered. Because of the perceived risks of physician and facility self-interests driving increased utilization, there has been a movement toward value-based reimbursement, which is supposed to balance treatment effectiveness, cost, and cost-effectiveness.
Oklahoma Benefits Program Setting an Example: A Cost-Effective Bundled Payments Option for State Employees
Yuexin Tang, PhD, Xingyue Huang, PhD, Jinan Liu, PhD, R. Ravi Shankar, MD, Michael L. Ganz, PhD, Swapnil Rajpathak, MD, DrPH
Type 2 diabetes mellitus (T2DM) affects approximately 30.3 million individuals in the United States, a number that is expected to grow to almost 36 million by the year 2030.
Impact of Step Therapy Restrictions in Diabetes Care
Major Cardiovascular Events in Patients with Gout and Associated Cardiovascular Disease or Heart Failure and Chronic Kidney Disease Initiating a Xanthine Oxidase Inhibitor
JoAnne Foody, MD, Robin S. Turpin, PhD, Beni A. Tidwell, BS, Debra Lawrence, PhD, Kathy L. Schulman, MS
Gout is a metabolic disorder that causes flares of arthritis in the joints and occurs with the onset of inflammation as a result of excess serum uric acid in the blood (ie, hyperuricemia) and the deposition of crystals in tissue.
The Growing Role of Real-World Evidence in Clinical Decision-Making
Comparing the Cost of Treatment with Octreotide Long-Acting Release versus Lanreotide in Patients with Metastatic Gastrointestinal Neuroendocrine Tumors
Rajeev Ayyagari, PhD, Maureen Neary, PhD, MS, Shang Li, MS, Ariel Rokito, BS, Hongbo Yang, PhD, Jipan Xie, MD, PhD, Al B. Benson III, MD, FACP, FASCO
Economic Impact of Increased Utilization of Multivariate Assay Testing to Guide the Treatment of Ovarian Cancer: Implications for Payers
Burton S. Brodsky, MD, Gary M. Owens, MD, Dennis J. Scotti, PhD, MBA, Keith A. Needham, BS, Christina L. Cool, MPH
Ovarian cancer is the eighth most common cancer among women, but ranks fifth in cancer-related causes of death, the majority of which are detected in late stages, after the cancer has metastasized.
Economic Impact of Using Tests to Guide the Treatment of Patients with Ovarian Cancer
Michael S. Broder, MD, MSHS, Tiffany P. Quock, MS, PhD, Eunice Chang, PhD, Sheila R. Reddy, PhD, RPh, Rajni Agarwal-Hashmi, MD, Sally Arai, MD, Kathleen F. Villa, MS
Cancer is costly. As new cancer therapies become available that extend survival, and as the US population ages and continues to grow, the cost of cancer care is estimated to reach almost $158 billion in 2020, according to the National Cancer Institute.
More Data Analysis Is Needed to Improve Outcomes, Lower Costs, and Maximize Appropriate Resource Use
Costs and Effectiveness of Mindfulness-Based Art Therapy versus Standard Breast Cancer Support Group for Women with Cancer
Katherine M. Prioli, BS, Laura T. Pizzi, PharmD, MPH, Kathryn M. Kash, PhD, Andrew B. Newberg, MD, Anna Marie Morlino, PharmD, Michael Matthews, BS, Daniel A. Monti, MD
The results of several studies have demonstrated that women and men with a cancer diagnosis benefit from interventions to reduce distress and improve quality of life (QOL). However, little is known about the costs and effectiveness of such interventions.
Creative Therapeutic Activities and Support Groups Benefit All Those Involved in Cancer Care
Medication Adherence, Treatment Patterns, and Dose Reduction in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Abiraterone Acetate or Enzalutamide
Page 4 of 7
Results 31 - 40 of 64
Results 31 - 40 of 64